©2025 Stanford Medicine
Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Not Recruiting
Trial ID: NCT02596997
Purpose
Provide patients with serious AdV infection or disease access to treatment with BCV.
Official Title
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Stanford Investigator(s)
Rajni Agarwal
Professor of Pediatrics (Stem Cell Transplantation)
Eligibility
Inclusion Criteria:
* Confirmed serious AdV infection based on clinical symptoms and laboratory testing showing AdV in the blood or other bodily fluids
* Able to swallow medication, either tablet or liquid
Exclusion Criteria:
* Previous dosing with Brincidofovir
* If female, not pregnant or trying to become pregnant
Intervention(s):
drug: Brincidofovir
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305